Fifth Third Bancorp cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 33.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,469 shares of the company’s stock after selling 17,435 shares during the quarter. Fifth Third Bancorp’s holdings in Guardant Health were worth $6,148,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. MCF Advisors LLC raised its holdings in Guardant Health by 755.0% in the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after acquiring an additional 151 shares in the last quarter. NFSG Corp purchased a new position in Guardant Health in the third quarter worth approximately $33,000. Jacobi Capital Management LLC purchased a new position in Guardant Health in the third quarter worth approximately $35,000. Fulcrum Asset Management LLP purchased a new position in Guardant Health in the third quarter worth approximately $37,000. Finally, Hollencrest Capital Management acquired a new position in Guardant Health during the 1st quarter worth approximately $41,000. 92.60% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Guardant Health
In related news, Director Steve E. Krognes sold 6,674 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the transaction, the director directly owned 7,906 shares of the company’s stock, valued at $1,389,400.44. This trade represents a 45.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Amirali Talasaz sold 37,500 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the completion of the transaction, the chief executive officer directly owned 37,500 shares in the company, valued at $6,343,500. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,039 shares of company stock worth $9,088,877 over the last 90 days. 5.60% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Guardant Health
Guardant Health Stock Down 5.1%
GH stock opened at $144.03 on Tuesday. The business has a 50 day moving average price of $168.29 and a 200 day moving average price of $133.16. The stock has a market cap of $19.49 billion, a price-to-earnings ratio of -39.14 and a beta of 1.67. Guardant Health, Inc. has a fifty-two week low of $74.55 and a fifty-two week high of $191.05.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46. The business had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. The business’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period last year, the company earned ($0.74) earnings per share. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -3.08 EPS for the current year.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Further Reading
- Five stocks we like better than Guardant Health
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
